|
Press Releases
Signal Transduction Collaboration December 5, 2011 — Dr. Graham Jack and his colleagues at IBI offer collaborative support in signal transduction studies for a proposal submitted by the Johns Hopkins School of Medicine to the Maryland Stem Cell Research Foundation entitled “Generating Neutrophils from hESC/[PSC via Expanded Myeloid Progenitors."
Post Doctorial Fellowship Collaboration May 26, 2011 — Dr. Graham Jack and his colleagues at Innovative Biosensors enter collaboration with Dr. Yang Song to support her Maryland Stem Cell Research Foundation Fellowship study of “Signals Cooperation with RUNX1 to Specify Adult HSC from hESC."
Innovative Biosensors licenses its BioFlash-E technology to PathSensors, Inc. November 30, 2010 — Innovative Biosensors agreed to license its BioFlash-E technology for the rapid detection of pathogens in biodefense and environmental applications.
About Innovative Biosensors
Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. Innovative Biosensor’s technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital acquired infections. Additional information is available at www.innovativebiosensors.com.
About PathSensors
PathSensors was formed in 2010. More information can be found at www.pathsensors.com
IBI Announces Departure of President & CEO, Joe Hernandez ROCKVILLE, MD, August 10, 2009 — Joe Hernandez, Founder, President & CEO of Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, announced his resignation effective August 7, 2009. Hernandez will continue to advise the company for several months thereafter. (Download PDF)
Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System ROCKVILLE, MD and EMERYVILLE, CA, February 24, 2009 — Innovative Biosensors, Inc. (IBI), and ProGenTech Limited, two emerging leaders in life science & diagnostics, today announced an agreement to jointly develop a rapid, integrated diagnostic system. The system will incorporate Innovative Biosensor’s proprietary Cellular Analysis and Notification of Antigen Risks and Yields (“CANARY®”) technology, a cell-based approach for quickly detecting various pathogens, into a modified version of ProGenTech’s Entura Lite™ platform with integrated optical detection capabilities. IBI will commercialize the developed product and financial terms of the deal were not disclosed. (Download PDF)
Innovative Biosensors, Inc. and the University of Maryland Receive Funding for Handheld Biosensor Development ROCKVILLE, MD, February 25, 2008 — Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, today announced the company’s selection for funding for a partnership proposal, with the A. James Clark School of Engineering at the University of Maryland, from The National Consortium for Measurement and Signatures Intelligence (MASINT) Research NCMR. (Download PDF)
Innovative Biosensors, Inc. Launches BioFlash-E™ Biological Detector ROCKVILLE, MD, November 13, 2007 — Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, today announced that it has launched the BioFlash-E™ Biological Aerosol Collection, Detection and Identification System. (Download PDF)
Innovative Biosensors, Inc. (IBI) Awarded $1.6 Million Contract for Biological Defense of Critical Buildings ROCKVILLE, MD, October 2, 2007 — Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, today announced that it has been awarded a contract to provide reagents and technical support for the proprietary CANARY™ technology-based detection and identification system installed and implemented at one of the most important structures in the National Capitol Region. (Download PDF)
Innovative Biosensors and Massachusetts Institute of Technology Announce Licensing Agreement for Biosensor Technology. Gaithersburg, MD, PRNewswire, November 20, 2003 — "Innovative Biosensors Inc., a privately held pioneering developer of rapid diagnostic technologies, today announced that the Company has obtained an exclusive license for the CANARY™ biosensor technology developed at Massachusetts Institute of Technology (MIT) Lincoln Laboratory." (Download PDF)